Vistagen Therapeutics (VTGN) Cash from Investing Activities (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Cash from Investing Activities of -$99000.0 for Q1 2026, down 195.19% sequentially from $104000.0 in Q4 2025, and down 118.79% YoY from $527000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Cash from Investing Activities for 16 years, with the latest figure at -$99000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 118.79% year-over-year to -$99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$877000.0 (up 93.33% YoY) and the FY2026 annual result came in at -$877000.0, up 93.33% from the prior year.
- Cash from Investing Activities slipped to -$99000.0 in Q1 2026 per VTGN's latest filing, from $104000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $527000.0 in Q1 2025 and troughed at -$7.8 million in Q3 2024.
- A 5-year average of -$988406.7 and a median of -$94000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 527900.0% in 2023, then jumped 1917.24% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$12500.0 in 2022, then sank by 156.0% to -$32000.0 in 2023, then plunged by 1218.75% to -$422000.0 in 2024, then jumped by 124.64% to $104000.0 in 2025, then sank by 195.19% to -$99000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$99000.0, $104000.0, and -$94000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99,000.00 |
| Mar 31, 2026 | -99,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | -94,000.00 |
| Sep 30, 2025 | -94,000.00 |
| Jun 30, 2025 | -788,000.00 |
| Jun 30, 2025 | -788,000.00 |
| Mar 31, 2025 | 527,000.00 |
| Mar 31, 2025 | 527,000.00 |
| Dec 31, 2024 | -422,000.00 |
| Dec 31, 2024 | -422,000.00 |
| Sep 30, 2024 | -7.79 Mn |
| Sep 30, 2024 | -7.79 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -5.47 Mn |
| Mar 31, 2024 | -29,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | -32,000.00 |
| Dec 31, 2023 | -32,000.00 |